Derivation of Genea016 human embryonic stem cell line

Area of Science:

• * Stem Cell Biology
• * Reproductive Medicine
• * Genetics

Background:

• * Human embryonic stem cells (hESCs) are crucial for regenerative medicine and disease modeling.
• * Characterization of new hESC lines is essential for expanding available research tools.
• * Ethical considerations and consent are paramount in hESC derivation.

Purpose of the Study:

• * To derive and characterize a novel human embryonic stem cell line, named Genea016.
• * To confirm the pluripotent nature and genetic stability of the Genea016 cell line.
• * To ensure the cell line is free from common contaminants.

Main Methods:

• * Derivation from an ART blastocyst via Inner Cell Mass (ICM) outgrowth on inactivated human feeders.
• * Karyotyping, Comparative Genomic Hybridization (CGH), and Short Tandem Repeat (STR) analysis for genomic verification.
• * Immunocytochemistry for pluripotency markers (Nanog, Oct4, Tra1-60, SSEA4) and PluriTest analysis.
• * Alkaline Phosphatase (AP) activity assay and Mycoplasma testing.

Main Results:

• * Genea016 demonstrated typical pluripotent stem cell morphology.
• * Genomic analysis confirmed a 46, XX karyotype and female allele pattern.
• * High expression of pluripotency markers: 95% Oct4, 98% SSEA4, 77% Nanog, 53% Tra1-60.
• * PluriTest score of 28.4 and Novelty score of 1.37 indicated pluripotency.
• * The cell line tested negative for Mycoplasma and contamination.

Conclusions:

• * The Genea016 hESC line is a well-characterized, pluripotent resource.
• * Its confirmed genetic stability and pluripotency make it suitable for various research applications.
• * The successful derivation from a commercially consented ART blastocyst highlights advancements in ethical stem cell sourcing.